Novartis’ Sandoz splurges on a trio of GSK antibiotics, doubling down with a $500M bet on a field struggling to combat resistant microbes
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line […]